Evox Therapeutics
6 known investors
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.
BiotechDeep Tech
Investors · 6
In the news
Frequently asked questions
- What does Evox Therapeutics do?
- Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.
- Who are Evox Therapeutics's investors?
- Evox Therapeutics's investors include OrbiMed, Oxford Science Enterprises, Panacea Venture, Cowen Healthcare Investments, GV (Google Ventures), REDMILE.